Enable Biosciences to Co-Sponsor Paris Diabetes Conference

Enable Biosciences to Co-Sponsor Paris Diabetes Conference

Nov 3, 2022. South San Francisco, CA. Enable Biosciences, a leading diabetes and COVID diagnostics firm and CLIA- and CAP-certified laboratory, announced that they will be co-sponsoring the 2023 Immunology of Diabetes Society Congress in Paris, France.

The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving the understanding and treatment of type 1 diabetes. Every 18 months, the IDS Congress is held in locations around the world. In 2023, the IDS Congress will be held in Paris, France, and administered by Universite Paris Cite and Sorbonne Universite.

Each IDS Congress hosts the Islet Autoantibody Standardization Program (IASP). IASP aims to harmonize the performance of islet autoantibody assays across international labs. These assays are critical for predicting the risk of advancing to and diagnosing type 1 diabetes. Enable Biosciences’ Antibody Detection by Agglutination-PCR assay has performed amongst the best assays in the 2018 and 2020 IASP programs and will be evaluated again in the 2023 IASP.

“We are delighted to support such a prestigious congregation of the very best scientific minds in type 1 diabetes. IDS and IASP have been fertile grounds for collaborations and new scientific directions and we look forward to reuniting with old friends and meeting new colleagues in Paris in 2023,” said Peter Robinson, Ph.D., COO of Enable Biosciences.

Other co-sponsors of the IDS Congress include JDRF, the Helmsley Trust, Eli Lilly, and Novo Nordisk.

Click here to read more about 2023 IDS Congress.

About Enable Biosciences: Enable Biosciences is a South San Francisco-based

diagnostics company commercializing licensed technology from UC Berkeley to develop and deploy bioassays for type 1 diabetes, COVID-19, and food allergy. Their proprietary diagnostics platform enables the ultrasensitive detection of biomarkers at the earliest stages of disease when it is potentially most easily and effectively treatable for the best outcomes. Enable operates a CLIA- and College of American Pathologists (CAP) - certified high complexity reference laboratory in South San Francisco. 

For more about Enable, visit www.enablebiosciences.com

For press inquiries, email press@enablebiosciences.com.

Previous
Previous

Enable Biosciences Participates in JDRF One Walk to Raise Funds for Type 1 Diabetes

Next
Next

Enable Biosciences Joins the JDRF One Walk to Raise Funds and Awareness for Type 1 Diabetes